Evidence map›Paper›PMID 38916801›Full record

ReviewCurrent cardiology reports2024

Is Intensive Blood Pressure Control Indicated in Older Patients with Hypertension?

Thwe Htay, Mariela Lane, Narges Khanjani, Aliasghar Arabi Mianroodi, Sarah Ream-Winnick

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current cardiology reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Thwe HtayPaul L. Foster School of Medicine, Texas Tech University Health Sciences Center at El Paso, El Paso, TX, U.S.A.. Thwe.htay@ttuhsc.edu.
Mariela LanePaul L. Foster School of Medicine, Texas Tech University Health Sciences Center at El Paso, El Paso, TX, U.S.A.
Narges KhanjaniPaul L. Foster School of Medicine, Texas Tech University Health Sciences Center at El Paso, El Paso, TX, U.S.A.
Aliasghar Arabi MianroodiPaul L. Foster School of Medicine, Texas Tech University Health Sciences Center at El Paso, El Paso, TX, U.S.A.
Sarah Ream-WinnickWashington University School of Medicine in St. Louis, St. Louis, MO, U.S.A.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewThis review aims to evaluate intensive blood pressure control in older adults, assessing its necessity, effectiveness, benefits and risks including cardiovascular outcomes, adverse events, quality of life, and overall mortality. RECENT

findingsRecent studies have supported that intensive antihypertensive treatment lowers the rates of cardiovascular events compared to standard treatment in older patients with hypertension, and it may also reduce the risk of cognitive decline. Intensive blood pressure lowering strategies are associated with reduced risk of cardiovascular morbidity and mortality as well as all-cause mortality, without compromising quality of life or functional status, and are relatively well tolerated in this patient population. Evidence suggests that maintaining systolic blood pressure below 130 mm Hg can yield cardiovascular and cognitive benefits in older patients with hypertension, particularly among those at risk of myocardial infarction or stroke. However, clinicians should vigilantly monitor for adverse events and engage in shared decision-making when pursuing intensive blood pressure goals tailored to individual risks and benefits.

Indexed as

Antihypertensive AgentsBlood PressureHypertensionQuality of LifeAgedBlood Pressure DeterminationCardiovascular DiseasesHumansAntihypertensive AgentsBlood pressureCardiovascular outcomesHypertensionIntensive blood pressure controlOlder adults

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.